Trial Outcomes & Findings for Sexual Dysfunction in Gynecologic Oncology Patients (NCT NCT03801031)

NCT ID: NCT03801031

Last Updated: 2022-12-06

Results Overview

Pain is measured by using the visual analog scale for pain, which is a scale of 0-10, utilizing numbers and face illustrations to describe pain level. Pain level is measured on a 0-10 point scale, 0 indicating no pain and 10 indicating the worst pain possible.

Recruitment status

TERMINATED

Study phase

PHASE4

Target enrollment

4 participants

Primary outcome timeframe

9 months

Results posted on

2022-12-06

Participant Flow

Subjects will complete nine short surveys at their initial visit, assessing physical, psychological, and social elements related to sexuality. Subjects will then have the tumor reduction surgery. Twelve weeks after surgery, each subject will be asked to complete the same nine-survey packet. Once the second packet is completed, subjects will be randomized to receive either the lidocaine solution or a placebo using permuted block technique based on cancer origin.

Participant milestones

Participant milestones
Measure
Lidocaine
Patients being treated for gynecologic cancer assigned aqueous lidocaine solution as intervention to use during sexual encounters. Lidocaine Topical: Many women treated for gynecologic cancer complain of sexual dysfunction and discomfort. It is thought that topical lidocaine application prior to sexual encounters may have reduced discomfort and improved overall quality of life during and following cancer treatment. The use of the lidocaine solution/placebo is the intervention.
Placebo
Patients being treated for gynecologic cancer assigned placebo solution as intervention to use during sexual encounters. Placebo: Placebo solution intervention used to validate the effects of the lidocaine solution usage.
Overall Study
STARTED
3
1
Overall Study
COMPLETED
1
0
Overall Study
NOT COMPLETED
2
1

Reasons for withdrawal

Reasons for withdrawal
Measure
Lidocaine
Patients being treated for gynecologic cancer assigned aqueous lidocaine solution as intervention to use during sexual encounters. Lidocaine Topical: Many women treated for gynecologic cancer complain of sexual dysfunction and discomfort. It is thought that topical lidocaine application prior to sexual encounters may have reduced discomfort and improved overall quality of life during and following cancer treatment. The use of the lidocaine solution/placebo is the intervention.
Placebo
Patients being treated for gynecologic cancer assigned placebo solution as intervention to use during sexual encounters. Placebo: Placebo solution intervention used to validate the effects of the lidocaine solution usage.
Overall Study
Lost to Follow-up
1
0
Overall Study
Unable to comply
1
0
Overall Study
Withdrawal by Subject
0
1

Baseline Characteristics

Sexual Dysfunction in Gynecologic Oncology Patients

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Lidocaine
n=3 Participants
Patients being treated for gynecologic cancer assigned aqueous lidocaine solution as intervention to use during sexual encounters. Lidocaine Topical: Many women treated for gynecologic cancer complain of sexual dysfunction and discomfort. It is thought that topical lidocaine application prior to sexual encounters may have reduced discomfort and improved overall quality of life during and following cancer treatment. The use of the lidocaine solution/placebo is the intervention.
Placebo
n=1 Participants
Patients being treated for gynecologic cancer assigned placebo solution as intervention to use during sexual encounters. Placebo: Placebo solution intervention used to validate the effects of the lidocaine solution usage.
Total
n=4 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Age, Categorical
Between 18 and 65 years
2 Participants
n=99 Participants
1 Participants
n=107 Participants
3 Participants
n=206 Participants
Age, Categorical
>=65 years
1 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants
Age, Continuous
56 years
n=99 Participants
52 years
n=107 Participants
55 years
n=206 Participants
Sex: Female, Male
Female
3 Participants
n=99 Participants
1 Participants
n=107 Participants
4 Participants
n=206 Participants
Sex: Female, Male
Male
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
White
1 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
n=99 Participants
1 Participants
n=107 Participants
3 Participants
n=206 Participants
Region of Enrollment
United States
3 participants
n=99 Participants
1 participants
n=107 Participants
4 participants
n=206 Participants

PRIMARY outcome

Timeframe: 9 months

Population: Study terminated prior to completion. Data not collected. Enrollment was halted prematurely and will not resume. Participants are no longer being examined or treated.

Sexual function measured by the Female Sexual Function Index (FSFI) survey, a 19-item self-report survey measuring sexual function. Item responses are on a 5-point scale and the total scores range 2 to 36 points, considering that the higher the score obtained, the better the sexual function of the woman.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: 9 months

Population: Study terminated prior to completion. Data not collected. Enrollment was halted prematurely and will not resume. Participants are no longer being examined or treated.

Pain is measured by using the visual analog scale for pain, which is a scale of 0-10, utilizing numbers and face illustrations to describe pain level. Pain level is measured on a 0-10 point scale, 0 indicating no pain and 10 indicating the worst pain possible.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 9 months

Population: Study terminated prior to completion. Data not collected. Enrollment was halted prematurely and will not resume. Participants are no longer being examined or treated.

Mean Change in Patient Health Questionnaire 9 (PHQ-9), a 9-item self-report instrument to screen for depression. Responses range from 0-3 and the scores range from 0-27, the higher total score indicates more depression.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 9 months

Population: Study terminated prior to completion. Data not collected. Enrollment was halted prematurely and will not resume. Participants are no longer being examined or treated.

Mean change in Generalized Anxiety Disorder 7-item scale (GAD-7), a brief self-report instrument of 7 items to assess generalized anxiety disorder. Responses range from 0-3 and the scores range from 0-21, the higher total score indicates more anxiety.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 9 months

Population: Study terminated prior to completion. Data not collected. Enrollment was halted prematurely and will not resume. Participants are no longer being examined or treated.

Mean change in Social Provisions Scale, a 24-item self-reported survey measuring perceived social support to assess confounders on sexual function. Responses range from 1-4 and higher total scores indicate greater social connection.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 9 months

Population: Study terminated prior to completion. Data not collected. Enrollment was halted prematurely and will not resume. Participants are no longer being examined or treated.

Mean change of Rosenberg's Body Self-Esteem Index, a 10-item self-report survey assessing global self-worth by measuring both positive and negative feelings about the self. Total scores range between 0 and 40; higher scores indicate better self-esteem.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 9 months

Population: Study terminated prior to completion. Data not collected. Enrollment was halted prematurely and will not resume. Participants are no longer being examined or treated.

Scores of Severity of Posttraumatic Stress Symptoms-Adult survey, a 9-item self-report instrument that assesses severity of posttraumatic stress disorder following a particular event or experience. Responses range from 0-4, 0 indicating no distress and 4 indicating extreme distress. Each item is measured on a 5-point scale (0=not at all; 4=extremely). Total score can range from 0-36 or averaged for 0-5. The higher scores indicate more severe PTS distress.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 9 months

Population: Study terminated prior to completion. Data not collected. Enrollment was halted prematurely and will not resume. Participants are no longer being examined or treated.

Presence, Severity, or Mean Change in Adverse Childhood Events Index, a 10-item self-report scale measuring types of physical, verbal, and emotional childhood trauma. Items are responded with yes or no. The total score is the sum of yes responses and range from 0-10. Higher total scores indicate more adverse childhood experiences.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 9 months

Population: Study terminated prior to completion. Data not collected. Enrollment was halted prematurely and will not resume. Participants are no longer being examined or treated.

Mean Change in SF-12, a 12-item self-report measure of perceived general health status and disability. Responses include yes or no or ranges on 5- or 6-point scales. Higher total scores indicate more disability.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 9 months

Population: Study terminated prior to completion. Data not collected. Enrollment was halted prematurely and will not resume. Participants are no longer being examined or treated.

Mean Change in Dyadic Adjustment Scale (DAS), a 32-item self-report measure of couple satisfaction. Responses are 5- or 6-point scales or yes or no. Total scores range from 0 to 151. Higher total scores indicate higher adjustment and satisfaction in intimate relationships.

Outcome measures

Outcome data not reported

Adverse Events

Lidocaine

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Placebo

Serious events: 0 serious events
Other events: 0 other events
Deaths: 1 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

David Bender, MD

University of Iowa

Phone: 319-356-2015

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place